



Uppsala, 6 February, 2006

Resistentia Pharmaceuticals receives regulatory approval to begin phase I clinical trial of its novel universal allergy immunotherapy

Resistentia Pharmaceuticals announced today that its Clinical trial application for a phase I trial of its universal allergy immunotherapeutic RP01 has been approved by the Swedish Medical Products Agency. The application was submitted on December 1st 2005 and its clearance will enable the Company to commence clinical investigations during March 2006.

"This approval represents our most important milestone so far in the development of our anti-IgE immunotherapeutic for the treatment of allergic disease" says Mr. Marcus Bosson, Chief Executive Officer of Resistentia.

The phase I trial will be performed in healthy volunteers and will primarily investigate the safety and tolerability of the product. In addition, the trial will also provide indicative information on efficacy and dose requirements.

"There still remains a large unmet medical need in patients with allergic asthma, and this innovative therapy represents a very promising alternative for many patients who are currently inadequately treated" says Dr. Lars Larsson, Chief Medical Officer.

About RP01

RP01 is a protein immunotherapeutic which induces the patient's immune system to produce antibodies against Immunoglobulin E (IgE), the key mediator of allergic reactions. The resulting anti-IgE antibodies are capable of blocking allergic reactions independently of the triggering factor (such as pollen or dust mite). RP01 has been investigated in a series of preclinical studies and has displayed strong efficacy in combination with an excellent safety profile. RP01 will primarily target allergic asthma. Other potential indications include allergic rhinitis and peanut allergy.

About Resistentia Pharmaceuticals

Resistentia Pharmaceuticals AB is a privately held biotech company developing innovative immunotherapies that target allergy/asthma and inflammatory disorders. Founded in 1998, the Company has developed an industrial organisation with experiences ranging from molecular immunology, pre-clinical and clinical drug development to industrial biopharmaceutical production. In addition to its lead anti-IgE immunotherapeutic, Resistentia has initiated pre-clinical development of an immunotherapeutic against complement factor C5a for the treatment of rheumatoid arthritis and other autoimmune diseases.

For more information, contact Chief Executive Officer **Marcus Bosson**, phone +46-706938281, marcus.bosson@resistentia.se

Resistentia

Resistentia Pharmaceuticals AB
Visiting address: Kungsängsvägen 25
Box 853, SE-751 08 Uppsala
Sweden

Tel: +46 (0)18 65 39 00
Fax: +46 (0)18 65 39 10
Internet: www.resistentia.se
VATno. SE556554158701